CONFLICT OF INTEREST STATEMENT
ONCOLOGY, EVENTS
Yutaka Fujiwara: personal fees from Amgen, AstraZeneca, Bristol Myers Squibb, Chiome Bioscience, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly, Novartis, ONO Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Taiho, Takeda, and Yakult, and grants from AnHeart Therapeutics and MSD outside the submitted work; Yasutoshi Kuboki: grants and personal fees from AbbVie, Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Daiichi‐Sankyo, Genmab, GlaxoSmithKline, Incyte, Lilly, Ono, Taiho, and Takeda; Masayuki Furukawa: nothing to disclose; Nobumasa Mizuno: grants from Incyte during the conduct of the study; and grants and personal fees from ASLAN Pharmaceuticals, AstraZeneca, Eisai, FUJIFILM Toyama Chemical, MSD, NanoCarrier, Novartis, Ono Pharmaceutical, Seagen, Taiho Pharmaceutical, and Yakult Honsha; Hara Hiroki: grants or contracts from Amgen, Astellas, AstraZeneca, Bayel, BeiGene, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Dainippon Sumitomo, Janssen, Merck Biopharma, MSD, Ono Pharmaceutical, and Taiho; consulting fees from Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Dainippon Sumitomo, MSD, Ono Pharmaceutical; payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from Asahi Kasei, Bayer, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Kyowa Hakko Kirin, Lilly, Merck Biopharma, MSD, Ono Pharmaceutical, Sanofi, Taiho, Takeda, and Yakult; Tatsuya Ioka: personal fees from Incyte, Ono Pharmaceutical, and Taiho Pharmaceutical outside the submitted work; Makoto Ueno: grants and personal fees from Astellas Pharma, AstraZeneca, Chugai Pharmaceuticals, DFP, Eisai, Incyte, Merck Biopharma, MSD, Nihon Servier, Ono Pharmaceutical, and Taiho Pharmaceutical; Yasuo Takahashi: Nothing to disclose; Shunji Takahashi: grants from Incyte during the conduct of the study; grants and personal fees from AstraZeneca, Bayer, Bristol Myers Squibb, Chugai, DAIICHI‐SANKYO, Eisai, MSD, Novartis, Ono pharmaceutical, and TAIHO, outside the submitted work; Shinji Takeuchi: grants and personal fees from Array BioPharma, Chugai, CMIC, Eli Lilly, Loxo Oncology, Ono, Pfizer, and Takeda; Chenwei Tian: employee and shareholder of Incyte Corporation; Christine Lihou and Tao Ji: former employees and shareholders of Incyte Corporation; Toshio Shimizu: grants from Incyte during the conduct of the study; grants and personal fees from 3D‐Medicine, AbbVie, Astellas, AstraZeneca, Bristol Myers Squibb, Chordia Therapeutics, Daiichi‐Sankyo, Eisai, LOXO/Eli Lilly, Novartis, Pfizer, PharmaMar, Symbio Pharmaceuticals, and Takeda Oncology, outside the submitted work.